Study details
Enrolling now
Rimegepant Trial for Migraine Triggers
Medstar Health Research Institute
NCT IDNCT07301008ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
60
Study length
about 1.4 years
Ages
18+
Locations
1 site in VA
What this study is about
Researchers are testing whether Rimegepant can help prevent migraine attacks triggered by specific things like exercise, alcohol, or air travel. The trial will last about 509 days and involve adults with a history of migraine triggers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Rimegepant 75 MG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
rimegepant
Drug routes
oral (Disintegrating Oral Tablet)
Body systems
Neurology